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Abstract
Tissue engineering of the skin is used for various applications. However, to develop 
treatments for skin pathologies such as psoriasis, robust pathological skin models 
are needed. The purpose of the work presented in this chapter was to optimize the 
production of more reproducible psoriatic skin substitutes by modifying the origi-
nal self-assembly method. Substitutes were produced according to the self-assembly 
method partially modified. The culture flasks of 25 cm2 were replaced by 6-well and 
12-well plates. Fibroblasts were cultured in 6-well and 12-well plates with ascorbic 
acid until they form manipulable sheets, which were superimposed and incubated for 
7 days to form a dermal layer. Afterwards, keratinocytes were seeded on the dermal 
layer forming an epidermal layer. Then, the substitutes were raised to the air-liquid 
interface and cultured 21 days before being analyzed. Analyses demonstrated that 
psoriatic substitutes have a significantly thicker epidermis than healthy substitutes 
and the persistence of nuclear structures in corneocytes, with original and both modi-
fied methods. Immunofluorescence markers such as filaggrin, loricrin, and keratin 14 
have confirmed these results. However, some differences were observed in substi-
tutes produced with 12-well plates. Modifications made to the original method for 
the production of psoriatic substitutes are effective and lead to highly reproducible 
substitutes more suitable for pharmacological testing.
Keywords: tissue engineering, cell culture, skin substitutes, psoriasis, self-assembly 
approach, in vitro
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1. Introduction
1.1. Skin
The integumentary system is the largest and heaviest organ of the body [1, 2]. This organ 
is divided into three distinct layers: the epidermis (superficial layer), the dermis (intermedi-
ate layer), and the hypodermis (deepest layer). Its main function is to protect the body from 
external aggressions, such as chemical, mechanical, thermal, microbial, and UV rays [3, 4]. It 
is therefore a physical, biological, and immunological barrier. The epidermis, the outer layer 
of the skin, predominantly ensures this barrier function by a constant renewal of keratino-
cytes, the epidermal cells. Keratinocytes differentiated into five layers: from the stratum basale 
(stratum germinativum), in which skin stem cells are found, to the stratum spinosum, stratum 
granulosum, stratum lucidum, and stratum corneum, which is the outer layer where keratinocytes 
have lost their nuclei and are completely keratinized [5]. Keratinocytes from this layer, also 
called corneocytes, will gradually detach to cause the phenomenon called desquamation. The 
highly regulated process of differentiation involves specific proteins to maintain this epider-
mal structure, and deregulation of these proteins expression can induce skin pathology such 
as psoriasis.
1.2. Psoriasis
Psoriasis is an erythematous-squamous dermatosis touching both men and women. This 
chronic skin pathology affects 2–3% of the world’s population [6, 7], which correspond to 
approximately 125 M people [8]. This pathology is characterized by a hyperproliferation and 
an abnormal differentiation of keratinocytes resulting in reddish and whitish plaques [5]. At a 
cellular level, histopathological characteristics consist of acanthosis, parakeratosis, hyperkera-
tosis, agranulose, and papillomatosis [9, 10]. The disease’s etiology is still unknown. However, 
environmental and immune factors, as well as genetic predispositions, would act together 
to trigger psoriasis [10, 11]. This disease seriously affects the quality of life of patients due 
to the appearance of their skin and the side effects of drugs. Existing treatments cause many 
severe side effects such as nephrotoxicity, hepatotoxicity, immunosuppression, teratogenicity, 
and no curable treatments have been found [12–14]. Moreover, several comorbidities may be 
related to psoriasis, such as major cardiac events, type 2 diabetes, and psoriatic arthritis [6].
1.3. In vivo and in vitro psoriatic skin models
The skin is a complex organ. Thus, the production of representative and reproducible skin 
models is a constant challenge. The use of ex vivo human skin biopsies would be more conve-
nient, since with skin biopsies, it is possible to observe the mechanisms and interactions of the 
human skin. However, because of skin donor availability and inter-individual variability, the 
use of ex vivo biopsies is not practical, and thus, the development of new models is important. 
Over the years, there has been a lot of progress in the field of tissue engineering [15]. Tissue 
engineering of the skin is used for various clinical applications and in fundamental research 
such as for drug development. Now, with the development and optimization of in vivo and 
in vitro models, it is possible to research new treatments for a skin disease by studying, for 
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example the antioxidant and antiproliferative potentials, and the toxicology of molecules or 
extracts [16, 17], to study the mechanism of action of compounds [18] and to perform percuta-
neous absorption studies, and thus study the permeability of the skin, the diffusion rate, and 
the site of action of compounds [19, 20].
1.3.1. In vivo models
Many approaches are used to obtain animal models as representative as possible to the 
human pathology. Spontaneous mutations, like the homozygous asebia, xenotransplantation, 
like the severe combined immunodeficient mice (SCID) and the athymic nude mouse, and 
genetic models, such as the CD18 hypomorphic mice model, the K14/TGF-α, and the involu-
crin/INF-γ, have been used over the years to study psoriasis but all of them displayed some 
limitations [21–23]. Animal models are mostly used to study specific aspects of the pathology. 
The development of a representative animal model can be expensive.
1.3.2. In vitro models
There are two types of models: monolayer models (dermal or epidermal) and bilayer substi-
tutes. Monolayer models use only one cell type, keratinocytes or fibroblasts, and will be used 
to study a specific characteristic or to understand the role of a certain cell type in pathologies 
such as psoriasis. However, these models exclude interactions between different cell types. 
Bilayer models displayed two layers of skin: dermis and epidermis, which allow the study 
of skin complexity more representatively. The challenge of skin engineering is to reproduce 
the complexity and the functionalities of a pathological skin. There are different in vitro psori-
atic skin models, which include interesting pathological features. Various pathological bilayer 
skin models were developed using a collagen gel as dermal equivalent. Most of these studies 
involve pathological keratinocytes seeded on a dermis made of collagen and fibroblasts [24, 
25], but there are also studies where a full-thickness psoriatic skin biopsy is incorporated into 
the dermal equivalent [26]. These models have been useful to better understand the disease 
and the interactions between fibroblasts and keratinocytes [26, 27]. However, the main disad-
vantage of these models is the use of an exogenous material, which does not represent exactly 
the properties of the human dermis. To counter the use of exogenous material such as collagen, 
some research teams have used de-epidermized dermis to produce their psoriatic skin models 
[28–30]. Although these equivalents demonstrate several psoriatic features, the use of these 
models for pharmaceutical studies would require an excessive amount of skin biopsies. Thus, 
a pathological model free of exogenous material that can generate many samples at a time is 
still required for pharmaceutical research.
Our team has developed a psoriatic skin model based on a self-assembly method, which is 
free of exogenous material [31]. This model has been characterized towards its permeability, 
lipid organization and response to antipsoriatic drugs [32, 33]. This basic model has also been 
improved by the addition of other cell types such as endothelial cells in order to reproduce the 
angiogenesis observed in vivo [34]. These studies have confirmed that our psoriatic skin sub-
stitute model produced according to the self-assembly approach maintained many character-
istics of the disease including the presence of a disorganized and thicker epidermis compared 
with normal skin substitutes [31]. This self-assembly approach allows the understanding of 
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pathological skin complexity through the possibility of: (1) dissecting step by step the mecha-
nisms of skin pathologies according to which kinds of cells are present in the model at that 
time and/or (2) using various cell combinations such as healthy fibroblasts and healthy kera-
tinocytes, which can be compared with healthy fibroblasts and pathological keratinocytes. 
Although the self-assembly method is very effective for the reconstruction of substitutes used 
in basic mechanisms studies, it required an optimization of its original protocol to consider 
a productive capacity of it in the pharmaceutical industry. Thus, the aim of this work was to 
improve the original self-assembly method to allow the reconstruction of more reproducible 
psoriatic skin substitutes that could be used for pharmacological testing.
2. Modified self-assembly methodology
As mentioned previously, our team has developed a model of in vitro psoriatic skin substitutes 
using the self-assembly method. In this present research, the production of the tissue-engineered 
psoriatic skin substitutes was done according to the self-assembly method partially modified, 
using 6-well plates and 12-well plates [31, 35] (Table 1 and Figure 1). All methods were also 
compared to the reconstruction of healthy skin substitutes. Briefly, pathological fibroblasts were 
cultured 28 days with Dulbecco-Vogt modification of Eagle’s medium (DMEM) supplemented 
with 10% fetal calf serum, 100 UI/ml penicillin G, 25 μg/ml gentamicin, and 50 μg/ml ascorbic 
acid until they form manipulable sheets. Then, these fibroblast sheets were detached, and two of 
them were superimposed to form a new dermal equivalent. Subsequently, they were incubated 
for 7 days to allow the fusion of the two sheets and thus form the new layer. After this period, 
pathological keratinocytes were seeded on the dermal equivalent to form a new epidermal layer. 
Seven days later, the substitutes were raised to the air-liquid interface to promote cell differentia-
tion and obtain the different epidermal layers. Skin substitute biopsies were taken at 21 days after 
being raised to the air-liquid interface and analyzed by histology and immunohistochemistry.
2.1. Results
2.1.1. Macroscopic results
Healthy skin substitutes reconstructed using either the original or modified methods 
(Figure 2A–C) showed a uniform and opaque epidermis recovering all the seeding area 
within the anchoring paper (white contours). For substitutes produced with psoriatic cells, 
Self-assembly 
method
Culture surface 
area (cm2)
Final size of substitute 
(usable) (cm2)
Volume of medium by 
fibroblast sheet (ml)
Anchoring 
papers
Original 25 3.87 5 Day 42
6-well plates 9.6 3.87 2 Day 0
12-well plates 3.8 1.27 2 Day 0
Table 1. Technical characteristics of the original method, the 6-well plate and the 12-well plate modifications.
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those reconstructed according to the original method and the 6-well plate modifications 
(Figure 2D–E) showed an irregular and contracted epidermis. Psoriatic skin substitutes pro-
duced using the 12-well plate modification (Figure 2F) demonstrated a more uniform epider-
mis compared to other methods.
2.1.2. Histology
Healthy skin substitutes reconstructed according to the original method, and the 6-well plate 
modification (Figure 3A and B) demonstrated a well-differentiated epidermis and similar 
Figure 1. Schematic representation of the self-assembly method. (A) Original self-assembly method: fibroblasts were 
cultured 28 days in 25 cm2 flasks for the production of fibroblast sheets. At day 28, flasks were opened with a soldering 
iron, and two sheets were superimposed to form a dermal equivalent. After one week, a metal ring was deposited on 
substitutes, and keratinocytes were seeded into the ring. Then, substitutes were cultured one more week in submerged 
conditions. At day 42, substitutes were placed on an anchoring paper and were raised to the air-liquid interface for three 
weeks. (B) Modified self-assembly method: fibroblasts were seeded in 6-well or 12-well plates in which anchoring paper 
have been previously placed. After 28 days of culture, two fibroblast sheets were easily superimposed and solidified 
with Ligaclip®. Dermal equivalents were cultured seven days before keratinocytes seeding. At day 42, substitutes were 
raised to the air-liquid interface and cultured for three weeks.
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characteristics. A thickening of the living epidermis was observed in substitutes produced with 
psoriatic cells using the original method, as well as in those reconstructed according to the modi-
fied protocols (Figure 3D–F). A less differentiated epidermis was observed in psoriatic substitutes 
produced according to the original method and the 6-well plate modification (Figure 3D–E), 
compared with the substitutes produced according to the 12-well plate modification (Figure 3F). 
The substitutes reconstructed according to the 12-well plate modification (Figure 3C and F) 
demonstrated a greater cell differentiation which results in a thickening of the stratum corneum.
2.1.3. Epidermal thickness
Thickness of skin substitutes’ living epidermis was measured with the AxioVision software. No 
significant differences were observed between the skin substitutes reconstructed with healthy 
cells according to the original method or the two new modifications (65.6 ± 13.9 vs. 69.0 ± 6.8 
vs. 78.39 ± 18.69 μm; Figure 4A). Measurements of psoriatic substitutes thickness reconstructed 
according to the original method, and the 6-well plate modification did not show any signifi-
cant differences between these two methods (93.50 ± 18.9 μm vs. 106.7 ± 23.7 μm; Figure 4B), 
while psoriatic substitutes produced with the 12-well plate modification demonstrated a sig-
nificant difference compared with the original method (130.8 ± 18.8 vs. 93.50 ± 18.9 μm).
Figure 2. Macroscopic analyses. Macroscopic appearance of healthy substitutes (A–C) and psoriatic substitutes (D–F). 
Substitutes were produced according to the original method (A and D), 6-well plate modification (B and E), and 12-well 
plate modification (C and F). Three substitutes of each condition were analyzed, and the results were confirmed with 
three independent experiments. Cells from two different healthy patients and three different psoriatic patients were 
used (scale bar = 1 cm).
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2.1.4. Immunofluorescence analyses
Immunofluorescent markers were used to compare protein expression. Late differentiation 
markers, such as filaggrin and loricrin, were observed in order to compare the different skin 
substitute models. The stratum granulosum of in vivo skin is characterized by the presence of 
keratohyalin granules and the expression of late differentiation markers, since their synthesis 
depends on keratohyalin granules [36, 37]. Moreover, late differentiation markers are found 
Figure 3. Histological analyses. Masson’s trichrome staining of healthy substitutes (A–C), psoriatic substitutes (D–F) 
and substitutes produced with the original method (A and D), 6-well plate modification (B and E), and 12-well plate 
modification (C and F). Three substitutes of each condition were analyzed, and the results were confirmed with three 
independent experiments. Cells from two different healthy patients and three different psoriatic patients were used 
(scale bar = 100 μm).
Figure 4. Thickness of the living part of epidermis. (A) Measurements of healthy substitutes produced with the original 
method, the 6-well plate modification, and the 12-well plate modification. (B) Measurements of psoriatic substitutes 
produced according to the original method, the 6-well plate modification, and the 12-well plate modification. The 
statistical significance was determined using ANOVA test (p < 0.05, n = 3, N = 3, 90 measurements by condition). Data 
presented are means ± S.D. (**) = p-value < 0.001.
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in the stratum granulosum. In healthy substitutes, filaggrin was expressed from the last layers 
of the stratum granulosum to the first ones of the stratum corneum (Figure 5A–C). In healthy 
substitutes produced according to the 6-well plate and 12-well plate modifications, a slight 
decrease of filaggrin was observed (Figure 5B and C). However, since keratohyalin granules 
are in lesser amount in psoriatic skin than normal skin due to abnormal keratinocytes dif-
ferentiation [38], expression of late differentiation markers are downregulated. In our psori-
atic substitutes, whether the original method was used or the two modifications to protocol 
were followed, filaggrin is reduced and almost missing (Figure 5D–F). Loricrin, another 
late differentiation marker found in stratum granulosum, was observed in healthy substitutes 
(Figure 5G–I). In the psoriatic substitutes, a decrease or an absence of loricrin was observed 
which is similar to in vivo psoriatic skin (Figure 5J–L).
Other markers, such as keratin 14, keratin 1, and laminin, were also observed. Keratin 14 (K14) is 
expressed in the basal layer of the epidermis and is gradually reduced until keratins 1 (K1) and 
10 (K10) are synthesized. In healthy substitutes produced according to the original method and 
the 6-well plate modification, keratin 14 was normally expressed (Figure 6A and B), whereas 
in healthy substitutes produced according to the 12-well plate modification, this keratin was 
still present in the stratum corneum (Figure 6C). In psoriatic skin, this protein is expressed in 
all epidermis such as observed regardless of the method used in the production of psoriatic 
substitutes (Figure 6D–F). Keratin 1 staining showed no difference between healthy substitutes 
reconstructed according to the original method or the 6-well plate modification (Figure 6G–H), 
while this keratin was overexpressed in stratum corneum of healthy substitutes produced 
according to the 12-well plate modification (Figure 6I). In psoriasis, keratin 1 is decreased 
such as observed in the psoriatic substitutes produced according to the original method or the 
6-well plate modification (Figure 6J–K), whereas psoriatic substitutes produced according to 
the 12-well plate modification showed a higher expression of this keratin in the stratum corneum 
compared to the other two (Figure 6L). Laminin expression was similar for all reconstructed 
healthy substitutes (Figure 7A–C), while for psoriatic substitutes, laminin expression seems 
more distributed through the dermis using the original method and the 6-well plate modifica-
tion (Figure 7D–E). Laminin staining of psoriatic substitutes produced according to the 12-well 
plate modification (Figure 7F) was similar to the healthy substitute expression.
2.2. Discussion
With psoriasis etiology still unknown, several in vivo models of psoriasis have been generated 
for a better understanding of the pathology. Genetically modified, spontaneous mutations, 
cytokine injections, xenografts, and gene knockout mouse models are all examples [21, 39–41]. 
Although these models showed psoriasis-like lesions, psoriasis is a specific human disease, 
and mouse skin does not represent characteristics of human skin such as epidermal thickness 
and structure, rete ridges and differences in certain immune cells [40, 41]. Due to the advances 
that have been made in the field of tissue engineering in the past years, it has been possible 
to develop in vitro psoriatic skin models to understand the disease, improve the development 
of new treatments, and limit the use of animals [24, 25, 28, 42]. Our team has developed a 
representative psoriatic skin model reconstructed according to a self-assembly method show-
ing in vivo features of psoriasis such as hyperproliferation and abnormal differentiation of 
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keratinocytes [31]. However, each model has limitations, and some of the model developed in 
our team is the large number of cells required for the production of skin substitutes, in addi-
tion to complex manipulations that may generate less reproducibility. Therefore, the optimi-
zation of the production of psoriatic skin substitutes with the aim of making them suitable 
models for their use in pharmacological testing remains a challenge.
Figure 5. Filaggrin and loricrin staining. Expression of filaggrin (red) in healthy substitutes (A–C), psoriatic substitutes 
(D–F) and substitutes produced according to the original method (A and D), the 6-well plate modification (B and E), and 
the 12-well plate modification (C and F). Expression of loricrin (green) in healthy substitutes (G–I), psoriatic substitutes 
(J–L) and substitutes produced according to the original method (G and J), the 6-well plate modification (H and K), and 
the 12-well plate modification (I and L). The nuclei were stained with Hoechst (blue). Three substitutes of each condition 
were analyzed, and the results were confirmed with three independent experiments. Cells from two different healthy 
patients and three different psoriatic patients were used (scale bar = 100 μm).
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Previous studies of our group have shown that this psoriatic skin model demonstrated phe-
notypic characteristics of in vivo psoriasis [31–33]. In the present study, it is demonstrated that 
the improvements made to the original self-assembly method did not affect the psoriatic phe-
notype of the substitutes. In vivo psoriatic features are still expressed in the substitutes recon-
structed according to the 6-well plate and 12-well plate modifications to protocol. Indeed, 
Figure 6. Keratin 14 and keratin 1 staining. Expression of keratin 14 (green) in healthy substitutes (A–C), psoriatic 
substitutes (D–F) and substitutes produced with the original method (A and D), the 6-well plate modification (B and 
E), and the 12-well plate modification (C and F). Expression of keratin 1 (green) in healthy substitutes (G–I), psoriatic 
substitutes (J–L) and substitutes produced according to the original method (G and J), the 6-well plate modification (H 
and K), and the 12-well plate modification (I and L). The nuclei were stained with Hoechst (blue). Three substitutes of 
each condition were analyzed, and the results were confirmed with three independent experiments. Cells from two 
different healthy patients and three different psoriatic patients were used (scale bar = 100 μm).
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in both new protocols, a significant increase in the living epidermis thickness of psoriatic 
substitutes is observed compared with their respective healthy substitute counterparts as for 
the original method. Interestingly, the epidermal thickness of psoriatic substitutes produced 
according to the 12-well plate modification was significantly thicker than those produced 
according to the original method. This difference could be explained by the same seeding 
number of keratinocytes in a smaller seeding area for the 12-well plate protocol. Thus, this 
induces an increase of acanthosis. Considering histological analysis, our model stands out 
from other models of in vitro psoriatic skin that did not show acanthosis [24, 25]. However, 
based on these histological observations, the 6-well plate modification to protocol seems to be 
the most representative compared with the original protocol.
Differentiation of psoriatic skin is characterized by the altered expression of several epider-
mal proteins [43]. In a normal differentiation process (approximately 28 days), the basal layer 
transit amplifying cells differentiate and migrate into upper epidermal layers and synthesize 
important proteins involved in the differentiation and the skin barrier function such as filag-
grin, loricrin, and keratins [36, 37, 44]. Filaggrin is normally synthesized from a precursor, 
profilaggrin, found in the granular layer. This protein is a key role in the formation of the 
cornified envelope [37]. In skin disease, such as psoriasis, expression of filaggrin is decreased, 
such that it is sometimes even absent due to an altered differentiation process and a reduction 
or an absence of the granular layer (agranulose) [38, 45, 46]. Loricrin, a major component of 
the cornified envelope, is stored in granules of the stratum granulosum, and its expression is 
also decreased or absent in psoriatic skin [36, 47]. In agreements with these observations, these 
features were observed with the substitutes reconstructed according to the original method 
Figure 7. Laminin staining. Expression of laminin (green) in healthy substitutes (A–C), psoriatic substitutes (D–F) and 
substitutes produced according to the original method (A and D), the 6-well plate modification (B and E), and the 12-well 
plate modification (C and F). The nuclei were stained with Hoechst (blue). Three substitutes of each condition were 
analyzed, and the results were confirmed with three independent experiments. Cells from two different healthy patients 
and three different psoriatic patients were used (scale bar = 100 μm).
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and the two modifications to protocol (6-well plate and 12-well plate modifications). Indeed, 
filaggrin and loricrin were detected in healthy skin substitutes, whereas their absence was 
observed in psoriatic skin substitutes. This therefore confirms that the characteristics associ-
ated with the psoriatic phenotype are preserved with these new methods.
Keratins are intermediate filaments highly involved in epidermal structure and different 
types are expressed in the varying differentiation stages [48]. K5 and K14 are normally 
found in the basal layer of the epidermis, and they are progressively replaced by K1 and 
K10 in suprabasal layers [49]. However, in vivo psoriatic skin shows K14 in all layers of 
the epidermis, including the stratum corneum. This therefore suggests that the degradation 
mechanism of this keratin is altered in psoriasis [48, 50]. Moreover, in such hyperprolif-
erative diseases, a new pair of keratins, K6 and K16, is appearing, causing a decrease in 
the expression of K1 and K10 [48, 50–52]. In the present work, healthy and psoriatic skin 
substitutes reconstructed according to the original method and the 6-well plate modification 
to protocol have demonstrated the same K1 and K14 expression than in vivo. Thus, taking 
together, K1, K14, filaggrin, and loricrin results validated the conservation of psoriatic skin 
differentiation in the new 6-well plate modification. This suggests that the 6-well method 
would be a great alternative to the original method. In healthy substitutes produced fol-
lowing the 12-well plate modification, an abnormal presence of K14 and K1 was observed 
in the stratum corneum, showing a less efficient differentiation of keratinocytes. This can 
probably be explained by the higher number of cells seeded in the culture area. These obser-
vations demonstrated that the 6-well plate modification is more effective for the production 
of healthy substitutes than the 12-well plate modification.
Some studies suggested that alterations in the basal membrane of psoriatic skin play an 
important role in the abnormal proliferation and differentiation of psoriatic keratinocytes 
[53–55]. Indeed, the expression of proteins such as laminin, which is one of the main pro-
teins that forms the basal membrane, is decreased and disrupted in psoriatic skin unlike 
in healthy skin. In this last, laminin forms a linear and continuous structure [54]. Laminin 
expression in our skin substitutes produced with healthy cells regardless of the method 
(original method and two new modifications) was intense, continuous and more restricted 
to the basal lamina, demonstrating a good structure of the basal membrane. For psoriatic 
skin substitutes (original method and 6-well plate modification), the expression of lam-
inin was more distributed through the dermis compared to healthy substitutes, showing 
disorganization in the basal membrane. For the psoriatic skin substitutes reconstructed 
according to the 12-well plate modification, laminin staining was more compact and similar 
to healthy substitute expression. Interestingly, this observation is showing that the basal 
membrane was more organized, thus less similar to the psoriatic phenotype. These results 
showed that the 6-well plate modification is more representative of the in vivo psoriatic skin 
than the 12-well plate modification.
2.3. Conclusion
These new modifications to protocol provide several advantages in the production of skin 
substitutes. Indeed, the 6-well and 12-well plate modifications require almost 3 times fewer 
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fibroblasts and culture medium than the original method for the production of fibroblast sheets, 
which favorably reduce production costs. In addition, the use of plates and anchoring papers 
at the beginning of the production greatly facilitate the handling and the superposition of fibro-
blast sheets increasing the quality of the dermal equivalent. The anchoring papers allow the 
production of more reproducible and uniform size substitutes within the same experiment and 
between the different studies, which are essential for pharmaceutical studies. In conclusion, the 
modifications made to the original self-assembly method for the production of psoriatic sub-
stitutes are effective and demonstrate a comparable phenotype. However, the 6-well method is 
the one that leads to reconstructed substitutes with characteristics more similar to those seen in 
vivo. These modifications make it possible to obtain substitutes that are distinguished by better 
reproducibility making them new tools of choice for pharmacological analyses.
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